Investors

Unique Opportunity: Acurex Right Now

Acurex is currently putting together a Convertible Note, bridging to anticipated major value recognition in 2026, driven by a partnership deal. Acurex insiders are taking substantial positions in this Note.

We believe that Acurex today is at the intersection of validated science, massive unmet need, and the right strategic plan to unlock extraordinary value.

Acurex mirrors key elements seen in past breakthrough success stories—validated biology, clear patient impact, and strategic discipline.
Pharmaceutical partners approaching Acurex are seeking new mechanisms for neuroinflammation, oxidative stress, ferroptosis, mitophagy dysfunction, alpha‑synuclein pathology, and neuronal rescue. Acurex is advancing these mechanisms through differentiated T‑type calcium channel antagonists, 15‑LO inhibitors, and other novel programs.

The partner-first model reduces risk, accelerates translation and provides a leverage to build value.

Forward‑Looking Statement:

This communication contains forward‑looking statements, including statements about our research programs, development plans, future operations, and potential clinical or regulatory milestones. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially. Forward‑looking statements speak only as of the date made, and we undertake no obligation to update them except as required by law.